These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36532876)

  • 1. Integrative bioinformatic analysis of p53 and pathway alterations in two different lung cancer subtypes.
    Zhang Y; Williams-Villalobo A; Godavarthi JD; Shakoor F; Xiong S; Liu B
    Biochem Biophys Rep; 2023 Mar; 33():101404. PubMed ID: 36532876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
    Cao B; Wang P; Gu L; Liu J
    Oncol Lett; 2021 Apr; 21(4):249. PubMed ID: 33664813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Zengin T; Önal-Süzek T
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders.
    Liu B; Liu Y; Zou J; Zou M; Cheng Z
    Anticancer Agents Med Chem; 2022; 22(8):1541-1550. PubMed ID: 34315392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative bioinformatics analysis the clinical value of KMT5A in different subtypes of lung cancer.
    Liu S; Tian W; Li B
    Comput Biol Chem; 2022 Feb; 96():107603. PubMed ID: 34894606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
    PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
    Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
    Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic landscape and prognosis of patients with
    Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
    Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma.
    Li P; Yuan H; Kuang X; Zhang T; Ma L
    Medicine (Baltimore); 2022 Nov; 101(47):e31798. PubMed ID: 36451444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
    Ma X; Yang S; Jiang H; Wang Y; Xiang Z
    J Transl Med; 2021 Aug; 19(1):368. PubMed ID: 34446056
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Xue D; Lin H; Lin L; Wei Q; Yang S; Chen X
    Transl Cancer Res; 2021 Mar; 10(3):1284-1294. PubMed ID: 35116455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.
    Freudenstein D; Litchfield C; Caramia F; Wright G; Solomon BJ; Ball D; Keam SP; Neeson P; Haupt Y; Haupt S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma.
    Li N; Zhao J; Ma Y; Roy B; Liu R; Kristiansen K; Gao Q
    Oncol Lett; 2018 Sep; 16(3):3992-4000. PubMed ID: 30128019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.